Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
09 mars 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, March 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016.“In 2016, we...
Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
27 févr. 2017 09h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and...
Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock
24 janv. 2017 08h50 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the pricing of the previously announced concurrent...
Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
23 janv. 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell shares of its...
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
05 janv. 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for its...
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality
04 janv. 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the appointment of Marc L. Lesnick, Ph.D., as...
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration
07 déc. 2016 07h00 HE
|
Cascadian Therapeutics, Inc.
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...
Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C. Chamberlain, M.D.
28 nov. 2016 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the Company strengthened its leadership team...
Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split
23 nov. 2016 16h05 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18,...
Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio Breast Cancer Symposium
15 nov. 2016 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company’s lead product...